We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 29. | 장 마감 후 (AMC) | $-0.1 | — | — | $44.43M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.04 | — | — | $42.02M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.08 | — | — | $166.31M |
Consensus PT $12.5 · 2 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2025. 06. 26. | Goldman Sachs | — | 의견 유지 | Sell → Sell | — | Goldman Sachs: Sell |
| 2025. 04. 18. | Goldman Sachs | — | 의견 유지 | Sell → Sell | — | Goldman Sachs: Sell |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.02 | — | — | $124.01M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Stored first · Google News · Yahoo Finance (English)
Amarin (NASDAQ: AMRN) investors curb new share issues and limit equity pay tools - Stock Titan
Amarin (NASDAQ: AMRN) investors curb new share issues and limit equity pay tools Stock Titan
Amarin (NASDAQ: AMRN) narrows Q1 2026 loss as revenue grows modestly - Stock Titan
Amarin (NASDAQ: AMRN) narrows Q1 2026 loss as revenue grows modestly Stock Titan
Director at Amarin (NASDAQ: AMRN) gains ADS from RSU vesting - Stock Titan
Director at Amarin (NASDAQ: AMRN) gains ADS from RSU vesting Stock Titan
Amarin (AMRN) director exercises RSUs as ADS, shares withheld for tax - Stock Titan
Amarin (AMRN) director exercises RSUs as ADS, shares withheld for tax Stock Titan